FLOVENT HFA Rx
Generic Name and Formulations:
Fluticasone propionate 44mcg/inh, 110mcg/inh, 220mcg/inh; metered dose inhaler; CFC-free.
Indications for FLOVENT HFA:
Maintenance treatment of asthma as prophylactic therapy.
Limitations Of use:
Not for the relief of acute bronchospasm.
Previously on bronchodilators alone: initially 88mcg twice daily (approx. 12hrs apart); max 880mcg twice daily. Rinse mouth after use. Titrate to lowest effective dose after stability achieved. Re-evaluate if inadequate control.
<4yrs: not established. 4–11yrs: 88mcg twice daily (approx. 12hrs apart). Rinse mouth after use. Titrate to lowest effective dose after stability achieved. Re-evaluate if inadequate control.
Primary treatment of status asthmaticus or other acute attacks requiring intensive measures.
Maintain regular regimen. Infections. If exposed to chickenpox or measles, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with inhaled corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Change in vision or history of increased intraocular pressure, glaucoma, and/or cataracts; monitor. Monitor for reduction in bone mineral density if other osteoporosis risk factors exist; and for growth suppression in children; hypercorticism and HPA axis suppression (if occur discontinue gradually). Eosinophilic conditions. Hepatic impairment (monitor). Transferring from oral corticosteroids: see full labeling. Pregnancy. Nursing mothers.
Concomitant strong CYP3A4 inhibitors (eg, ritonavir, ketoconazole): not recommended.
Upper respiratory infection/inflammation, throat irritation, sinusitis, dysphonia, candidiasis, cough, bronchitis, headache; immunosuppression, adrenal suppression, bronchospasm.
Inhaler w. actuator (44mcg)—10.6g (120 inh); 110mcg, 220mcg—12g (120 inh)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma